【ABSTRACT】 Objective: To investigate DBC2 mutations in breast cancer patients and evaluate the relationship between the gene mutations and breast cancer susceptibility in Eastern China population. Methods: Mutation analyses of 285bp promoter sequence, coding exon 7 and its exon/intron boundaries of DBC2 were performed in thirty-two breast cancer specimens by polymerase chain reaction and direct sequencing. Eighteen benign breast tumor specimens were also anlysed as control. Results: No mutation in the promoter or exon 7 was found in both group.
Introduction
Breast cancer is one of the most common malignancies threatening women's healthy, more than 230,480 new cases of breast cancer will be diagnosed and 39,520 will die from the disease in the United States in 2011. The incidence rate of breast cancer in China was relatively lower before 1960's, but it has been increasing rapidly since 1970's. Dates from Shanghai Disease Prevention And Control Center showed that breast cancer has become the most common malignancy and ranks first among the cause of cancer death in Shanghai since 2005.Early stage breast cancer showed good outcomes. However, for most patients who were diagnosed with advanced cancer, the prognosis was very poor. Therefore, it is crucial to find new tumor markers in order to screen breast cancer susceptible population and improve the prognosis of the disease. DBC2 gene (deleted in breast cancer 2), also known as RhoBTB2, was first cloned from breast cancer tissues by Hamaguchi and his colleagues [1] . Resarches showed that DBC2 participates in varieties of cellular functions such as cell cycle control, apoptosis, cytoskeleton regulation, and protein transport [2] [3] [4] . The expression of DBC2 extinguished frequently in tumor tissues [1, 5, 6] , and reintroduction of DBC2 gene can inhibit the growth, migration and invasion of tumor cell [1, 7, 8] . Therefore, DBC2 is thought to play an important role in the carcinogenesis and progression of breast cancer. However, as a newly identified tumor suppressor gene, few
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researches on DBC2 in breast cancer have been reported up to now, even fewer in China. In our study, we analyzed the polymorphism in promoter and exon 7 of DBC2, as well as investigated whether the genotypic background contributes to oncogenesis of breast cancer in Chinese Han ethnic group.
Material and Method

Study subjects
Breast cancer samples were collected from Changhai Hospital. The resected specimens were immediately frozen in liquid nitrogen and stored at -80℃ until DNA extraction. The diagnosis of breast cancer was confirmed by pathological examination. Informed consent was obtained from each individual recruited for this study, and the study was approved by the Ethics commission of Second Military Medical University.
Polymerase chain reaction and DNA sequencing
Genomic DNA was extracted from tumor tissue using QIAamp DNA Mini Kits, and stored at -20 until amplification. 
Relationship between DBC2 mutation and clinicopathological characteristics
Discussion
DBC2, located in chromosome 8p21, is a newly identified tumor suppressor gene [1] .
Regulated by E2F1.DBC2 plays a key role in inducing cell apoptosis and inhibiting tumor growth, migration an invasion through interaction with CCND1, BRMS1 and Cul3 ubiquitin ligase complexes [2, 7, [9] [10] [11] . DBC2 mutation is correlated to the oncogenesis and development of varieties of malignant tumor, including breast cancer, gastric cancer and bladder cancer [1, 5, 6, [12] [13] [14] . Recently, Ohadi et al. reported two mutation sites ( -238G>A and -121C>T) in DBC2 promoter in breast cancer tissues, which abolished binding site for the transcription factors Sp1-1 and E2F respectively [12] . Knowles et al. discovered a missense mutation (1681G>A, causing protein 561G>S)in DBC2 7 exon in a bladder cancer sample [14] . Both the deletion of transcription factor biding site and missense mutation could alter gene expression.In our study,we conducted gene In summary，mutation in the promoter and exon 7 of DBC2 was not common in Chinese population, and may not contribute to the susceptibility for breast cancer in this region.
IVS7+53C>G was a common polymorphism in Chinese Han ethnicity. Our date showed IVS7+53C>G is correlation to the expression of HER2 and p53, further study is warranted to investigate whether IVS7+53C>G is a independence risk factor for breast cancer in a large population.
Previously studies showed DBC2 variations in expression is very frequent, while the gene mutation is rather infrequent [1, 6, 16] , indicated that epigenetics events may play much more important role in loss of DBC2 expression. Recently, Shi and his colleagues analyzed promoter methylation and DBC2 gene expression in a bladder cancer research by MS-PCR and RT-PCR.
They reported the frequency of methylation in DBC2 promoter was significantly higher in bladder tumor samples than that of corresponding normal tissues, and hyper-methylation was highly correlated to the gene inactive. They speculated that DBC2 inactivation by hyper-methylation may 6 be a crucial step in the process of cell carcinogenicity. Therefore, research on hyper-methylation at CpG island may be a new way for revealing the relationship between the inactivation of DBC2 and susceptibility for breast cancer, hence provide a novel molecular target for diagnosis, treatment and prognosis of the disease.
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